Myelodysplastic Syndromes: Low Blood Counts and Disease Monitoring

Myelodysplastic syndromes are a group of bone marrow disorders in which the body does not make enough healthy blood cells. Regular monitoring helps doctors understand the pace of the condition, manage low blood counts, and decide when treatment is needed.

Overview

Myelodysplastic syndromes, also known as MDS, are a group of disorders that affect the bone marrow, the soft tissue inside bones where blood cells are made. In MDS, the marrow produces blood cells that may be abnormal, immature, or unable to survive long enough in the bloodstream. As a result, a person may have low numbers of red blood cells, white blood cells, platelets, or a combination of these.

These low blood counts are called cytopenias. Low red blood cells can lead to anemia, low white blood cells may increase infection risk, and low platelets can make bruising or bleeding more likely. MDS can behave very differently from one person to another. Some people have a slow-moving condition that is monitored for years, while others need active treatment sooner.

MDS is considered a clonal bone marrow disorder, meaning it starts from a group of blood-forming cells that have acquired changes in their genetic material. In some patients, MDS can progress to acute myeloid leukemia, but this does not happen in everyone. Doctors use blood counts, bone marrow findings, chromosome changes, genetic mutations, and the person’s overall health to estimate risk and plan care.

Symptoms and Low Blood Counts

Many people with MDS are diagnosed after routine blood tests show low counts before any symptoms are noticed. When symptoms do occur, they are usually related to which type of blood cell is low and how severe the decrease is. Symptoms often develop gradually, so patients may adapt to fatigue or reduced stamina without realizing it is linked to anemia.

Low red blood cells may cause tiredness, shortness of breath with activity, dizziness, pale skin, chest discomfort in people with heart disease, or a faster heartbeat. Low neutrophils, a type of white blood cell important for fighting bacteria and fungi, can make infections more frequent, longer-lasting, or harder to clear. Low platelets may lead to easy bruising, small red or purple spots on the skin, nosebleeds, gum bleeding, or heavier-than-usual menstrual bleeding.

Symptoms that may be discussed during monitoring visits include:

• Changes in energy level, exercise tolerance, or breathlessness
• Fever, chills, mouth sores, cough, urinary symptoms, or repeated infections
• New bruising, bleeding, black stools, or blood in urine
• Unintentional weight loss, night sweats, or bone discomfort
• How often transfusions are needed, if the patient receives them

Causes and Risk Factors

In many patients, the exact cause of MDS is not known. MDS usually develops after acquired changes occur in the DNA of bone marrow stem cells during a person’s lifetime. These changes are not typically inherited from parents, and most people with MDS have no family history of the disease. The condition is more common in older adults, although it can occur at younger ages.

Some factors may increase risk. Previous treatment with chemotherapy or radiation therapy for another cancer can lead to therapy-related MDS, which may behave differently from MDS that develops without prior treatment. Long-term exposure to certain chemicals, such as benzene, and heavy tobacco exposure have also been associated with higher risk. Rare inherited bone marrow failure syndromes can increase the risk of MDS in children or younger adults, but these are uncommon.

Having a risk factor does not mean a person will develop MDS, and many people with MDS have no clear exposure history. For this reason, evaluation focuses on confirming the diagnosis, understanding the biology of the marrow cells, and assessing the person’s blood counts, symptoms, and general health rather than trying to identify a single cause.

Diagnosis

The diagnostic process usually begins with a complete blood count, often called a CBC. This test measures hemoglobin, white blood cells, neutrophils, and platelets. A blood smear may also be examined under a microscope to look at the size, shape, and maturity of blood cells. Doctors commonly check for other causes of low blood counts, such as vitamin B12 or folate deficiency, iron problems, kidney or liver disease, thyroid disease, inflammation, infections, medication effects, or autoimmune conditions.

If MDS is suspected, a bone marrow aspiration and biopsy are usually needed. These tests allow the medical team to examine marrow cell number, cell appearance, the percentage of immature blast cells, and signs of abnormal development called dysplasia. The procedure is commonly performed with local anesthesia, and the sample is sent for several types of laboratory analysis.

Chromosome testing, also called cytogenetics, and molecular testing for gene mutations are important parts of modern MDS evaluation. These results help classify the subtype of MDS, estimate the risk of progression, and guide treatment choices. Diagnosis is not based on one result alone; it is made by combining the patient’s history, blood counts, marrow findings, and genetic information.

Risk Stratification and Disease Monitoring

Monitoring is a core part of MDS care because the condition can change over time. Doctors use risk scoring systems that consider blood counts, marrow blast percentage, chromosome findings, and sometimes gene mutations. These systems help estimate whether the disease is more likely to remain stable or progress, and whether the main goal is symptom control, improving blood counts, or reducing the risk of transformation to leukemia.

For lower-risk MDS, follow-up may focus on symptoms, quality of life, CBC trends, transfusion needs, and signs of infection or bleeding. For higher-risk MDS, monitoring is often more intensive and may include repeat marrow evaluation to assess response to treatment or disease progression. The frequency of visits depends on the stability of blood counts, current treatment, and the patient’s overall condition.

Patients can support monitoring by keeping a record of test results, transfusions, infections, bleeding episodes, new medications, and symptoms between visits. A change in the pattern of blood counts is often more important than a single number. Because MDS care is individualized, patients are encouraged to ask what their risk category means, which results are being tracked, and what changes should prompt earlier contact with the care team.

Treatment Options

Treatment for MDS depends on the risk category, symptoms, severity of cytopenias, transfusion needs, genetic findings, age, other medical conditions, and the patient’s goals. Some people with stable, lower-risk MDS may not need immediate treatment and can be safely followed with regular monitoring. This approach is often called active surveillance or watchful waiting; it does not mean the condition is being ignored.

Supportive care is an important part of treatment. It may include red blood cell or platelet transfusions, medicines that stimulate blood cell production in selected patients, treatment of infections, and careful management of iron overload if repeated transfusions are needed. Some patients may benefit from specific medications based on their MDS subtype or chromosome changes. Others may receive disease-modifying therapies that aim to improve counts, reduce transfusion needs, or slow progression.

For selected patients, especially those with higher-risk disease and suitable overall health, an allogeneic stem cell transplant may be considered. This is the only treatment with curative potential for MDS, but it also carries significant risks and is not appropriate for everyone. Decisions about transplant require detailed discussion with a hematology and transplant team, including expected benefits, possible complications, donor availability, and the patient’s preferences.

Prevention, Self-Care, and Living With MDS

There is no guaranteed way to prevent most cases of MDS, especially when no clear cause is present. However, general health measures can help reduce complications and support well-being. Patients should avoid smoking, follow workplace safety guidance for chemical exposures, keep vaccinations up to date as recommended by their doctor, and report signs of infection promptly.

Self-care should be adapted to the person’s blood counts. With anemia, pacing activities and allowing rest periods may help conserve energy. With low platelets, patients may be advised to avoid activities with a high risk of injury and to ask before using medicines that can affect bleeding risk, such as aspirin or certain anti-inflammatory drugs. With low white blood cells, good hand hygiene, safe food practices, and early communication about fever are important.

Emotional support is also part of care. Living with a chronic blood disorder and repeated blood tests can be stressful, even when the condition is stable. Patients may benefit from asking clear questions, bringing a family member to appointments, and seeking support from counseling services or patient organizations. A balanced diet, regular gentle physical activity when approved by the doctor, and management of other conditions such as diabetes or heart disease can also improve resilience.

When to See a Doctor

A medical evaluation is important if routine blood tests show unexplained anemia, low white blood cells, low platelets, or multiple low blood counts. People already diagnosed with MDS should contact their care team if symptoms change, if fatigue becomes more limiting, or if they develop signs of infection or bleeding. Fever in a person with low neutrophils should be treated as medically important and assessed promptly.

Patients should also seek medical advice for unusual bruising, persistent nosebleeds, blood in stool or urine, shortness of breath at rest, chest pain, fainting, or new confusion. These symptoms can have many causes, but in the setting of low blood counts they should not be ignored. The goal is timely assessment and supportive treatment when needed.

Care for MDS is usually coordinated by a hematologist, often with input from pathology, genetics, infectious disease, transfusion medicine, and transplant specialists. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat blood disorders, including MDS, for international patients. Any treatment plan should be discussed with a qualified doctor who can interpret the patient’s specific test results and overall health situation.

Frequently asked questions

What are myelodysplastic syndromes?

Myelodysplastic syndromes are a group of bone marrow disorders in which blood-forming cells do not mature normally. This can lead to low red blood cells, white blood cells, platelets, or a combination. The condition varies widely, so some people are monitored without immediate treatment while others need active therapy.

Why do low blood counts happen in MDS?

In MDS, the bone marrow may contain many developing blood cells, but many of them are abnormal and do not become healthy circulating cells. Some die inside the marrow before reaching the bloodstream. This ineffective blood production causes cytopenias, which are low blood counts.

Does MDS always turn into leukemia?

No. Some people with MDS have a low risk of progression and may live for years with careful monitoring and supportive care. Others have higher-risk disease that is more likely to progress to acute myeloid leukemia. Doctors estimate risk using blood counts, bone marrow blast percentage, chromosome changes, gene mutations, and overall health.

How often should MDS be monitored?

The monitoring schedule depends on the risk category, blood count stability, symptoms, and current treatment. Some patients need blood tests every few weeks, while others may be followed at longer intervals when stable. The hematologist will adjust the schedule if counts change, transfusion needs increase, or new symptoms appear.

Can MDS be treated without chemotherapy?

Yes, many patients receive supportive treatments rather than traditional chemotherapy, especially in lower-risk MDS. These may include transfusions, medicines that stimulate blood cell production, infection management, or targeted approaches for specific subtypes. Higher-risk MDS may require disease-modifying therapy or consideration of stem cell transplantation in selected patients.

What should patients with MDS do if they develop a fever?

A fever can be important in a person with low white blood cells, especially low neutrophils. Patients with MDS should ask their care team in advance what temperature threshold requires urgent contact or evaluation. They should not self-treat a significant fever without medical advice.

Can lifestyle changes cure MDS?

Lifestyle changes cannot cure MDS, but they can support overall health and reduce some complications. Avoiding smoking, practicing good hand hygiene, staying current with doctor-recommended vaccines, eating safely, and managing other medical conditions can be helpful. Treatment decisions still need to be based on medical evaluation and blood or marrow findings.

References

• World Health Organization
• National Cancer Institute
• American Society of Hematology
• European LeukemiaNet
• National Comprehensive Cancer Network

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.